Summit Therapeutics Inc.
SMMT
$18.91
-$1.55-7.58%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.20% | 45.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -177.65% | 266.04% | |||
| Total Operating Expenses | 12.40% | 30.86% | |||
| Operating Income | -12.40% | -30.86% | |||
| Income Before Tax | -8.80% | 6.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.80% | 6.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.80% | 6.84% | |||
| EBIT | -12.40% | -30.86% | |||
| EBITDA | -12.40% | -30.88% | |||
| EPS Basic | -7.24% | 9.26% | |||
| Normalized Basic EPS | -7.23% | -20.70% | |||
| EPS Diluted | -12.00% | 11.11% | |||
| Normalized Diluted EPS | -7.23% | -20.70% | |||
| Average Basic Shares Outstanding | 1.49% | 2.65% | |||
| Average Diluted Shares Outstanding | 1.49% | 2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
